Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Utility of Cell-free DNA Methylation Markers for the Response Prediction of Systemic Treatment for Hepatocellular Carcinoma

NCT05573217 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05573217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05573217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Utility of Cell-free DNA Methylation Markers for the Response Prediction of Systemic Treatment for Hepatocellular Carcinoma
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2021
Completion date
June 30, 2023
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cell-free methylation markers